Medical Marijuana, Inc. Subsidiary HempMeds® Brasil To Sponsor 8th ABN-RJ/ANERJ Congress in Rio de Janeiro

SAN DIEGO, Sept. 26, 2017 — Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil is proud to sponsor the 8th Brazilian Academy of Neurology/Association of Neurology of the State of Rio de Janeiro (ABN-RJ/ANERJ) Congress Workshops taking place from September 28-30 at the Windsor Barra Convention Center in Rio De Janeiro, Brazil.

The 8th ABN-RJ/ANERJ Congress aims to bring together professionals working in Neurology/Neurosciences and related fields to deepen the scientific debate and the development of knowledge in leading areas such as neurogenetics, neuroimaging, neuroimmunology, translational neurology, among others.

“We are proud to sponsor this neurological-focused event that we believe will focus attention toward improving the quality of treatment for people with neurological disorders,” said Medical Marijuana, Inc.’s CEO Dr. Stuart Titus. “With its neuroprotective, anti-oxidative and anti-inflammatory effects, cannabidiol (CBD) is making new inroads into neurological research. Given potential neuro-regenerative effects, CBD further holds the potential to revolutionize neurological medicine.  By showing great promise for neurodegenerative diseases like Parkinson’s, Alzheimer’s, Multiple Sclerosis and Epilepsy – we continue to be excited about research opportunities throughout Latin America. We are further encouraged by the Brazilian medical community’s interest in new treatment solutions that cannabis and CBD may offer to improve the quality of patient’s lives.”

HempMeds Brasil™ is the first company to offer legal medicinal cannabis products to Brazil after receiving import approval to those suffering from specific medical conditions. Most recently in February 2017, for the filling of a prescription for the first time for the Company’s hemp CBD oil product RSHO™ to treat patients in the Country suffering from Multiple Sclerosis. Additionally, doctors in Brazil can prescribe RSHO™ for any condition and HempMeds Brasil™ has worked with several cases including patients suffering from:

  • Epilepsy
  • Psoriasis
  • Pain
  • Cancer
  • Parkinson’s
  • Alzheimer’s
  • Migraine
  • Diabetes
  • Amyotrophic Lateral Sclerosis

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically-sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

About HempMeds® Brasil

HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for multiple conditions including; Epilepsy, Parkinson’s, Chronic Pain, Psoriasis, Cancer, Alzheimer’s, Diabetes, ALS, Multiple Sclerosis and Migraines. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
[email protected]